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circulating IGF-I and IGFBP-3 increase with milk (and 
dairy protein) intake (an estimated standardized effect size 
of 0.10 SD increase in IGF-I and 0.05 SD in IGFBP-3 per 
1 SD increase in milk intake). There was moderate evi-
dence that prostate cancer risk increased with IGF-I (Ran-
dom effects meta-analysis OR per SD increase in IGF-I 
1.09; 95% CI 1.03, 1.16; n = 51 studies) and decreased with 
IGFBP-3 (OR 0.90; 0.83, 0.98; n = 39 studies), but not with 
other growth factors. The IGFBP-3 -202A/C single nucleo-
tide polymorphism was positively associated with prostate 
cancer (pooled OR for A/C vs. AA = 1.22; 95% CI 0.84, 
1.79; OR for C/C vs. AA = 1.51; 1.03, 2.21, n = 8 studies). 
No strong associations were observed for IGF-II, IGFBP-1 
or IGFBP-2 with either milk intake or prostate cancer risk. 
There was little consistency within the data extracted from 
the small number of animal studies. There was additional 
evidence to suggest that the suppression of IGF-II can 
reduce tumor size, and contradictory evidence with regards 
to the effect of IGFBP-3 suppression on tumor progression.
Conclusion IGF-I is a potential mechanism underlying 
the observed associations between milk intake and prostate 
cancer risk.
Abstract 
Purpose To establish whether the association between 
milk intake and prostate cancer operates via the insulin-
like growth factor (IGF) pathway (including IGF-I, IGF-II, 
IGFBP-1, IGFBP-2, and IGFBP-3).
Methods Systematic review, collating data from all rel-
evant studies examining associations of milk with IGF, and 
those examining associations of IGF with prostate cancer 
risk and progression. Data were extracted from experimen-
tal and observational studies conducted in either humans or 
animals, and analyzed using meta-analysis where possible, 
with summary data presented otherwise.
Results One hundred and seventy-two studies met  the 
inclusion criteria: 31 examining the milk–IGF relation-
ship; 132 examining the IGF–prostate cancer relationship 
in humans; and 10 animal studies examining the IGF–pros-
tate cancer relationship. There was moderate evidence that 
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Introduction
Dairy consumption, and in particular milk, has been impli-
cated as a risk factor for prostate cancer, although results are 
inconsistent. The World Cancer Research Fund (WCRF)/ 
American Institute for Cancer Research (AICR) concluded 
in their 2014 expert report that there is limited evidence that 
milk increases risk [1]: the synthesized results of 15 of the 
21 studies identified as examining the association between 
dairy products and prostate cancer risk showed a 7% 
increased risk per 400 g of dairy products consumed per day 
(RR 1.07, 95% CI 1.02–1.12). However, observational stud-
ies have been hindered by milk consumption being recorded 
semi-quantitatively in some studies, with large differences 
between individuals in the same group, and therefore subject 
to attenuation of effects by measurement error. In addition, 
associations of milk intake with prostate cancer are suscepti-
ble to confounding by other diet and lifestyle factors.
Evidence to support the causality of observed positive 
associations of milk intake with prostate cancer could come 
from basic experimental studies. For example, a recent study 
[2] showed that milk stimulates the growth of prostate cancer 
cells in culture. In addition, evidence of underlying mecha-
nisms by which milk causes prostate cancer may shed some 
light on whether observational findings are likely to be accu-
rate. However, some way of systematically collating and 
synthesizing data from such disparate sources is required in 
order to avoid the selective interpretation of evidence.
Our overall objective in this work was to assemble the 
worldwide literature from human, animal, and genetic 
models to investigate whether any association between 
milk consumption and prostate cancer initiation or pro-
gression acts via the IGF pathway. The review was under-
taken as a case study in support of a novel framework for 
reviewing mechanistic studies of exposures and cancer; the 
milk–prostate cancer association was not considered as the 
WCRF have already synthesised this literature. The frame-
work was commissioned by WCRF UK, as an extension of 
their Continuous Update of the 2007 Report [1].
Several mechanisms have been hypothesised by which 
milk could promote prostate cancer. First, increased calcium 
intake in people with high milk consumption may suppress 
the conversion of 25(OH) vitamin D to 1,25(OH)2 vitamin 
D, which has antiproliferative effects on human prostate 
cancer cells [3]. Second, milk is a rich source of oestrogens 
[4], which are associated with prostate cancer, although the 
mechanism of action is poorly understood [5]. Furthermore, 
the nutritionally regulated (including by milk intake [6]) 
insulin-like growth factor (IGF) signaling pathway has been 
highlighted in a number of studies as a probable factor in 
prostate cancer (PCa) initiation and progression [7–9].
Relevant mechanistic studies will frequently have an 
intermediate phenotype (in this case the IGF system) rather 
than cancer as an outcome, or the intermediate pheno-
type as the exposure for a cancer outcome. Therefore, we 
separately identified studies that linked our exposure of 
interest (milk) to the intermediate phenotype, and studies 
that linked the same intermediate phenotype to prostate 
cancer initiation or progression. Data from each evidence 
stream (human, animal, and genetic models) were critically 
appraised using specific risk of bias (RoB) protocols and 
graded using the Grading of Recommendations Assess-
ment, Development, and Evaluation (GRADE) tool. By 
combining the evidence from each study type and using 
strict RoB and GRADE protocols to ensure the inclusion 
of high-quality data only, our aim was to provide a compre-
hensive review of the milk–PCa relationship, focusing on 
IGF as a specific intermediate phenotype.
Materials and methods
Data sources
We carried out two searches to identify studies that inves-
tigated (i) associations between milk intake and IGF levels 
(milk–IGF); and (ii) associations between IGF levels and 
prostate cancer (PCa) outcomes (IGF–PCa). MEDLINE 
(1950–March 2014), EMBASE (1980–March 2014), BIOSIS 
(1969–March 2014) and CINAHL (1981–March 2014) were 
systematically searched. Searches were performed using key 
words (BIOSIS) or a combination of key words and subject 
headings (MEDLINE, EMBASE, and CINAHL). Full search 
terms are included in Supplementary Boxes 1–3.
Inclusion and exclusion criteria
We included original articles published in peer-reviewed 
journals (including supplements and meeting abstracts); 
reviews, books, commentaries, and letters were excluded. 
We included randomized controlled trials (RCTs), 
case–control, cohort, non-randomized experimental, and 
case-series studies in humans, as well as all animal stud-
ies, with the exception of those that used a known carcino-
gen alongside the exposure. This decision was based on the 
relevance of carcinogenic-initiated cancers within the con-
text of addressing whether milk causes prostate cancer ini-
tiation or its progression. We included both transgenic and 
xenograft animal models; although transgenic models were 
considered to be more relevant within a human context, 
xenograft models may give some insight into the biological 
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plausibility of the mechanism of action. Animal studies that 
only presented cell line data or used hallmarks of cancer as 
the outcome [10] were analyzed separately; thus the results 
are not presented here. There were no language restrictions.
Milk–IGF specific criteria
We included all papers that investigated associations of 
dairy and milk intake with IGFs and IGFBPs. Outcomes 
of interest were serum or plasma levels of IGF-I, IGF-II, 
and IGF binding proteins (IGFBP-1, -2, and -3). Exposures 
of interest were milk or milk products, including dairy pro-
tein or dairy product intake. Since different milk products 
contain different amounts of water and other substances, 
they were considered both separately and together so that 
any differences between the exposures could be observed. 
We included both RCTs and observational studies. The pri-
mary exposure of interest within this analysis was cow’s 
milk as a dietary environmental factor in relation to PCa 
risk; therefore, we excluded studies where the exposure was 
human breast milk, colostrum, soy milk or formula milk.
IGF–Prostate Cancer specific criteria
We included all papers that measured the association 
between the IGF pathway and prostate cancer outcomes. 
Exposures of interest were serum or plasma levels of IGF-
I, IGF-II, and IGF binding proteins (IGFBPs)-1, -2, and 
-3; expression levels of IGF-I, IGF-II, IGFBP-1, -2, and 
-3; IGF-I receptor (R), IGF-IIR genes and any other genes 
(or specific single nucleotide polymorphisms [SNPs]) with 
‘IGF’ as part of the gene name and that were part of the IGF 
pathway. Outcomes of interest included prostate cancer inci-
dence or prevalence, measures of progression (biochemical 
recurrence, local or distal metastases), and prostate cancer-
specific mortality. We included studies using healthy or 
benign prostatic hyperplasia (BPH) control subjects. We 
excluded papers if PCa was not a defined outcome.
Data extraction
After papers (milk–IGF and IGF–PCa) had been identi-
fied and collated, exact duplicates were excluded. Titles, 
author names, page numbers, years of publication, and jour-
nal names were analyzed to exclude any remaining dupli-
cates that had different entries in multiple databases due to 
typographical errors or reference style. The abstracts of all 
remaining papers were retrieved and independently screened 
by two of four possible assessors (SH, VV, AP, MG); where 
no abstract was available, or if the abstract provided insuf-
ficient information to inform a screening decision, the full 
text was retrieved for review. Any discrepancies between the 
two assessors were resolved by a third assessor.
Data were independently extracted in duplicate for each 
study (SH, RL), with disagreements resolved by discussion. 
Data extracted for all study types included details of study 
or model design, study population (location and sample 
size), exposure or intervention, outcome, statistical meas-
ure (including details of any model adjustments), and effect 
estimates (including mean values, standard deviation [SD], 
P values, and odds ratios [OR] with any corresponding 95% 
confidence intervals [CI] as a continuous measure or by 
quantiles). For each study type (human studies [milk–IGF, 
IGF–PCa] or animal models [IGF–PCa]), specific data 
were also collected (see Box1).
Box 1 Differences in data extracted for each study type
Milk–IGF IGF–prostate cancer
Human studies
 Study design: RCT, cross-
sectional, cohort
 Intervention: milk, dairy prod-
uct, dairy protein intake
 Outcome: type of IGF, IGFBP
 Measure of exposure (units)
 Sample size
 Average age of subjects
 Percentage of males in study
 Method of diet assessment
 Length of follow-up
 Ethnicity
 Study design: cohort, nested 
case control, case control
 Retrospective or prospective 
ascertainment of outcome with 
respect to exposure measure-
ment
 Intermediate phenotype: type 
of IGF and IGFBP, name of 
genes/SNPs/allele/number of 
repeats
 Study category: IGF levels, 
genetic, supporting  evidencea
 Control source (population, hos-
pital, population-based cohort, 
trial-based cohort)
 Control type (healthy, BPH, 
mixed BPH, and healthy)
 Sample type (serum, plasma)
 Method of exposure measure-
ment
 Age of cases and controls 
(including where possible, age 
at diagnosis)
 Time between sample collection 
and analysis
 PSA-detected or clinically 
detected study populations
 Mid-year of recruitment
 Study name
 Ethnicity
Animal studies
 All IGF-PCa animal studies
   Model design: transgenic, xenograft
   Outcome: tumor biometrics (various), hallmarks of cancer [10]
   Type of experimental and control models used
   Length of follow-up
a Studies which did not compare IGF biomarkers or genotypes in cases 
vs controls or against progression or mortality, but nevertheless may 
provide evidence on the role of the IGF pathway in prostate cancer. 
Examples include studies examining the association between prostate 
cancer risk and loss of imprinting in genes or haplotypes (as opposed 
to single nucleotide polymorphisms), and studies looking at progres-
sion of prostate cancer after treatment
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IGF–Prostate cancer studies
To minimize the risk of reverse causation (i.e., the secondary 
effects of PCa on IGF levels rather than the causal effects of 
IGF levels on PCa), we pragmatically classified human stud-
ies assessing IGF–PCa as prospective if there was a mean of 
2 years or more between the collection of samples and diag-
nosis; otherwise they were classified as retrospective. Where 
the time between sample collection and diagnosis was 
unclear, we conservatively classified the studies as retrospec-
tive. This classification may differ from how the studies were 
classified by the authors in the original publication.
For papers presenting data in several ways the order of 
choosing the data to be synthesized was (i) reported coeffi-
cients (log odds ratio [OR] or risk ratio per unit increase in 
exposure); (ii) quantile data (ORs stratified by quantiles of 
IGF) and (iii) continuous data presented as mean or median 
differences. We extracted data that were fully adjusted up 
to, but not including, mutual adjustment for a different 
growth factor (i.e., IGF-I adjusted for IGFBP-3 and vice 
versa). If more than one publication or study presented 
data on the same IGF biomarker from the same cohort, we 
extracted data from the study with the largest sample size.
During extraction, we divided human IGF–PCa stud-
ies into three categories that provided data on (i) the asso-
ciation between circulating levels of IGF or IGFBPs, ‘IGF 
level’ studies and prostate cancer outcome; (ii) IGF or 
IGFBP genes or SNPs, ‘genetic’ studies; and (iii) studies 
which provided neither (i) or (ii), but presented data rele-
vant to the relationship between the IGF pathway and PCa 
outcomes, termed as ‘supporting evidence.’ Studies exam-
ining free IGF levels, as opposed to total IGF levels, were 
not amenable to meta-analysis as they could not be com-
bined with total IGF levels and there were too few papers 
to meta-analyze alone. As such, studies examining free IGF 
levels were included in supporting evidence.
Milk–IGF studies
We extracted p values and sample sizes from all studies. If 
p values were not presented, 95% CIs and effect estimates 
were used to estimate the p value. Data for males were 
extracted in preference to females (because the ultimate 
outcome of interest was prostate cancer), followed by com-
bined data, then female only data.
Statistical analyses
Milk–IGF data
The main difficulty in combining all studies that exam-
ined the relationships of milk, dairy products, and dairy 
proteins with IGFs and IGFBPs was the degree of hetero-
geneity between these studies. Study designs ranged from 
RCTs conducted over decades to short-term observational 
studies; the exposures (milk, dairy protein, and dairy prod-
ucts) were both different and measured differently between 
studies; and study participants varied in age, ethnicity, and 
location. In addition, effect estimates were provided in dif-
ferent formats, such as percentage increases or ORs, often 
with too little information to estimate a standardized effect 
estimate.
We generated albatross plots [11] for each outcome 
to best interpret the results. An albatross plot is a scatter 
plot of study sample sizes against two-sided p values, with 
results separated according to the observed direction of 
effect. The albatross plot allows the p values to be inter-
preted in the context of the study sample size. Small stud-
ies appear toward the bottom of the plot and large studies 
toward the top. Different exposures are drawn using differ-
ent markers to facilitate identification of subgroup effects. 
Effect contours are superimposed on the plot to give an 
indication of the magnitude of effect both for individual 
studies, and for the association as a whole.
To provide additional information, a meta-analysis of 
P values was conducted using Stouffer’s Z score method 
of combining P values [12]; the one-tailed P value for the 
most common direction of effect across studies for each 
IGF was used to calculate the one-tailed combined p value 
across studies for each IGF.
IGF–Prostate cancer data
Types of data used
To compare data from multiple studies that examined rela-
tionships of growth factors with prostate cancer, we cal-
culated the log OR per standard deviation (SD) increase 
in exposure, as previously described in Rowlands et  al. 
[8]. The log OR per unit increase in exposure for studies 
presenting results as a difference in means between cases 
and controls was calculated using the method presented by 
Chêne and Thompson [13]. For studies presenting results 
within quantiles of exposure, the mean or median exposure 
was used in each quantile (if reported), and the log OR per 
unit increase in exposure was calculated using the method 
presented by Greenland and Longnecker [14], using the 
‘glst’ command in Stata [15]. When the mean or median 
in each quantile was not reported but instead a range of 
exposures in each group was, the mean exposure was 
estimated in each quantile using the method presented by 
Chêne and Thompson [13] (assuming a normal distribution 
of the exposure in the population). When no mean, median 
or range was reported, a normal distribution was assumed 
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based on the mean and SD of the group used to generate the 
quantiles (usually the controls). This distribution was used 
to calculate the quantile range, and thus the mean of each 
quantile. If only subgroup analyses were presented and not 
an overall case versus control group analysis, the subgroups 
were combined statistically by calculating pooled means 
and SDs. The log ORs per unit increase and their standard 
errors were converted to a per SD increase by multiply-
ing by the SD of the exposure. For quantile data, the SD 
was calculated using the method presented by Chêne and 
Thompson [13].
As in the Rowlands meta-analysis [8], a linear rela-
tionship between growth factors and prostate cancer was 
assumed, which can result in a different OR to a highest 
versus lowest quantile analysis. However, this method 
allowed the use of the middle quantiles of data, increasing 
the amount of available data.
Random effects and fixed effect meta‑analyses
We performed random effects and fixed effect meta-anal-
yses on all growth factors to calculate summary OR esti-
mates, using the ‘metan’ Stata command [16]. We calcu-
lated the  I2 statistic as a quantitative measure of the degree 
of inconsistency across studies [17]. Small study effects 
were assessed by inspection of funnel plots and computa-
tion of Egger and Begg tests [18, 19].
There was substantial inconsistency across studies in the 
IGF–PCa analysis (I2 > 65% for all growth factors). There-
fore, our primary results are from random effects models 
throughout this paper; we also present fixed effect results 
for comparison.
Subgroup analyses
To investigate whether growth factors were associated with 
advanced prostate cancers, we conducted a separate meta-
analysis using data from studies that examined this out-
come. The definition of advanced prostate cancers varied 
across studies; the combined definition of ‘advanced’ thus 
extends to non-localized cancers, Gleason score 7+ can-
cers, metastasized cancers, ‘high grade’ cancers (the defini-
tion of which varied between studies) or ‘aggressive’ can-
cers (which were a combination of advanced stage and high 
grade).
We produced forest plots for all growth factor and both 
prostate cancer outcome (all and advanced) analyses; these 
plots were stratified by prospective and retrospective stud-
ies, and PSA-detected and clinically detected studies. The 
difference between subgroup estimates was explored using 
the method of Altman and Bland [20].
Genetic data
Although many studies reported associations between vari-
ous SNPs and prostate cancer, only two genetic variants 
were examined by a sufficient number of studies to allow us 
to conduct meta-analyses: IGF-I CA repeats, and IGFBP-3 
-202 A/C polymorphisms. We included studies which pre-
sented results in a combinable way: for IGF-I CA repeats, 
19/X and X/X were both compared against 19/19 repeats 
in separate analyses, where X was anything other than 19. 
For IGFBP-3 -202 A/C polymorphism, A/C and C/C were 
both compared against A/A in separate analyses. If data 
were presented in the opposite direction, i.e., A/C and A/A 
against C/C, we transformed the results to allow these to 
be combined with other data. The meta-analyses for these 
genotypes were conducted in the same manner as in the 
IGF–PCa studies with forest and funnel plots produced, but 
not grouped by prospective/retrospective, as an individual’s 
genotypes do not change over time, and therefore should 
not be susceptible to reverse causation.
Risk of bias (RoB) and GRADE assessments
Due to the variety of studies included within the meta-
analysis and the need for consistent risk of bias assessment, 
we developed a tool to determine the overall risk of bias 
for each study using the categories of assessment from a 
draft of the ROBINS-I tool [21], and the questions to aid 
in assessing risk of bias from the CASP case–control and 
cohort questionnaires [22, 23]. Bias was assessed in six 
categories: Confounding, selection of participants, miss-
ing data, outcome measurement, exposure measurement, 
and results’ reporting. Each category contained ques-
tions designed to help assess the risk of bias; these varied 
depending on the study type (e.g., animal, human, genetic) 
and design (e.g., cohort, RCT, case–control) (Supplemen-
tary Box 4). An overall and category-specific risk of biases 
were assigned; either low, moderate, serious, critical, or 
unclear.
On the basis that circulating IGF levels increase with 
age from birth to young adulthood and then gradually 
decline into old age, any studies which did not age-match 
cases and controls or adjust for age within the analysis, 
and presented a difference of 5 or more years between the 
mean age of cases and controls, were categorized as criti-
cal RoB due to confounding and excluded from the analy-
sis. In addition, all observational studies that investigated 
serum levels of IGF in relation to PCa risk were given a 
moderate RoB status as a minimum, as it is unlikely that 
all confounding factors could be fully controlled for within 
observational designs. The majority of the human IGF–PCa 
cohort papers did not provide information on missing data 
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with regards to patients lost at follow-up, therefore these 
papers were considered to have at least a moderate RoB due 
to missing data.
All milk–IGF studies that used food frequency ques-
tionnaires, or used diet assessments involving information 
recall, were also given a moderate RoB rating as a mini-
mum due to measurement error when dietary recall is used 
as the only measure of exposure.
For milk studies, if only one RoB sub-category was 
found to be unclear, the level of bias the sub-category 
could have caused was taken into consideration. For exam-
ple, confounding could have a large impact on risk of 
bias, and therefore an unclear risk of bias in confounding 
would be assumed to be serious risk of bias. Conversely, 
results’ reporting has a relatively smaller impact on risk of 
bias, and therefore unclear risk of bias would be assumed 
to be moderate risk of bias. The overall risk of bias for a 
study was based on the sub-category with the largest risk of 
bias. Studies determined to have a critical risk of bias were 
excluded before analysis.
The GRADE rating for each exposure/outcome pair was 
calculated as per the GRADE protocol [24]. The RoB sta-
tus of each paper was used to inform the GRADE rating 
for each collection of papers within a study category (e.g., 
animal IGF–PCa). The overall GRADE rating was used to 
provide a measure of overall quality of the evidence pro-
vided by the results.
Results
Systematic searches of all four online databases identi-
fied 7,239 papers; 3,025 cross-database duplicates were 
removed, leaving 4,214 papers. After abstract screening, 
728 papers remained for full text review, including one 
additional paper from Rowlands et al. [8] that was not iden-
tified within the original search [25]. Of these, 172 papers 
met the inclusion criteria and were taken forward for data 
extraction (Fig. 1): 31 papers (representing 31 independent 
studies) examining the milk–IGF relationship; 132 papers 
(representing 125 studies) examining the IGF–prostate can-
cer relationship in humans; and ten papers (representing ten 
studies) examining the IGF–prostate cancer relationship in 
animals. One study had data relevant to both milk–IGF and 
IGF–PCa analyses [26].
None of the 31 milk–IGF studies were excluded due 
to RoB, and all were included in at least one albatross 
plot and narrative synthesis of different IGFs, except for 
two studies [27, 28] that looked at qualitatively different 
outcomes, which were excluded from the albatross plots 
and considered separately in the narrative synthesis. The 
total number of studies looking at each type of IGF was 
as follows (the two studies excluded from albatross plots 
shown in brackets): IGF-I, n = 28 (+2); IGF-II, n = 2 
(+1); IGFBP-1, n = 2; IGFBP-2, n = 2 (+1); IGFBP-3, 
n = 15 (+2). Three studies stratified results by ethnicity; 
the ethnicity subgroups were considered as separate data 
points in the albatross plots [29–31].
Of the studies included in the milk–IGF analysis, two 
had serious RoB (both retrospective cross-sectional stud-
ies) [32, 33]; 18 had moderate RoB (two prospective 
cohort studies; 16 retrospective cross-sectional studies) 
[27, 31, 34–49]; one had low RoB (non-randomized trial) 
[30]; and nine had unclear RoB (four RCTs, one non-ran-
domized trial, three prospective cohorts, and one retro-
spective cross-sectional study) [28, 29, 50–57].
No animal milk–IGF studies were included due to 
irrelevant exposures or outcomes of interest; the majority 
of animals were exposed to colostrum intake within the 
first 6 months of life as part of study designs.
Of the 132 human IGF–PCa studies, 89 had serum 
level IGF data available for meta-analysis; the remain-
ing 43 studies were considered as supporting evidence as 
they did not contain any data amenable to meta-analysis 
[58–100]. One study was considered as supporting evi-
dence since it presented data for free IGF-I in relation to 
PCa risk, rather than total serum levels of IGF-I [75].
Of the 89 studies with data for meta-analysis, 16 
had serious RoB (all retrospective) [101–116], 47 had 
moderate RoB (23 prospective, 24 retrospective) [8, 
26, 34, 117–160], eight had low RoB (all genetic only) 
[161–168] and seven had unclear RoB (five genetic only, 
two retrospective) [25, 169–174]. Eleven observational 
studies were excluded from the meta-analysis due to criti-
cal RoB (one prospective, one genetic, and nine retro-
spective [175–185]).
Seven studies were excluded from the meta-analysis 
as they presented data from the same group of partici-
pants with the same exposure and outcome variables as 
other included studies that contained more information 
(e.g., more participants) [34, 122, 153, 156–160], leaving 
71 unique studies for meta-analysis; 58 studies examin-
ing serum IGF levels (IGF-I: 51 studies; IGF-II: 10 stud-
ies; IGFBP-1: 4 studies; IGFBP-2: 6 studies; IGFBP-3: 39 
studies; IGF-I and IGFBP-3 Advanced PCa: 12 studies) 
and 18 examining IGF genetic data (IGF-I (CA)n repeats: 
5 studies; IGFBP-3 -202 A/C SNP: 8 studies; other SNPs: 
11 studies). Three papers did not contain enough informa-
tion in the paper to calculate an OR [25, 151, 174]; there-
fore data from the previous Rowlands meta-analysis were 
used [8], as Rowlands contacted the study authors for more 
information as part of the data extraction protocol.
Eight animal IGF–PCa studies were included within the 
animal analysis [186–193], and two animal studies were 
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included in supporting evidence [194, 195]; these studies 
did not have enough information to extract an effect esti-
mate or P value. The overall risk of bias in all animal stud-
ies was unclear.
An infographic displaying the main results of the 
human milk to IGF and IGF to PCa studies is presented in 
Fig. 2, showing the combined P values for the associations 
between milk and IGFs, and IGFs and PCa risk (includ-
ing advanced PCa risk), the direction of effect and the total 
number of participants from all studies.
Milk–IGF: human studies
Table  1 shows data extracted from studies examining the 
milk–IGF association. In general, studies examined the 
quantity of milk or dairy consumed through a food record 
or food frequency questionnaire, and used servings/weight 
of milk/dairy consumed per day/week, as the exposure 
(either categorically or continuously). The outcome (IGF 
levels) was measured using blood draws. The majority of 
studies were cross-sectional; prospective studies had a 
follow-up ranging from 1 week to 65 years. Interventional 
Fig. 1  Flow diagram depict-
ing the inclusion and exclusion 
process during the meta-anal-
ysis and the number of papers 
categorized into each study type 
for milk–IGF and IGF–PCa
Main Paper
31 human papers, 
representing 31 studies 
(*1 study also included in IGF-
prostate cancer arm)
121 human papers, 
representing 114 studies 
• 71 meta-analysis
o 58 serum IGF
o 18 genetic IGF
• 43 supporting evidence
10 animal papers, 
representing 10 studies 
• 8 analysis
• 2 supporting evidence
172* papers remained and were taken forward for data extraction 
(SH, RL)
31 milk-IGF papers 142 IGF-prostate cancer papers
7239 targeted papers identified
3025 duplicates removed
4214 papers remained after removal of duplicates
3488 papers excluded after review of title and abstract 
only (MG, SH, AP, VV)
726 papers remained after initial exclusion
557 papers excluded after full text review 
(MG, RL, VT, SH)
252 Irrelevant outcome/exposure 
142 cell line papers 
67 Short communications, abstracts, supplements, 
comments, patents, erratum  
41 Duplicates 
43 Reviews 
7 Pure efficacy of therapy
4 Books 
1 No information
729 papers for full text review
1 additional paper added from Rowlands analysis 2012 
(not picked up in original search: technical comment) 
2 additional papers included from review of Rowlands 
2012 & 2009 meta-analyses
11 critical RoB 
papers excluded
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studies generally supplemented the diet of the partici-
pants, rather than depriving one group of milk/dairy. The 
age range of participants when the outcome was measured 
varied between 2 and 86 years; the majority of studies 
focussed on Caucasians.
Data extracted from the 31 milk–IGF studies were 
unsuitable for standard meta-analysis methods of com-
bining effect sizes due to high levels of heterogeneity and 
differences in effect estimate formats (Tables 1, 2, 3). The 
studies investigated a range of exposures (including milk, 
milk beverages, dairy protein, and dairy products) that were 
quantified by a number of measures (such as density intake 
[g/1,000  kcal/day], percentage of energy intake and serv-
ings per day and grams per day).
Albatross plots were used to assimilate the data and vis-
ual inspection was used to provide an estimated standard-
ized effect estimate and a range of possible effect estimates 
for each outcome (Table  4). The effect estimates are not 
precise and are intended only as an indication of the magni-
tude of the effect estimate; a range of possible estimates is 
provided to highlight this fact. We present all standardized 
effect estimates for the milk–IGF association as the stand-
ard deviation (SD) increase in IGF protein per one stand-
ard deviation increase in the measure of exposure. One SD 
of milk varies across studies, especially as studies differ in 
presentation of milk units (e.g., grams per day, milliliters 
per day, portions per day). However, Hoppe [53] and Rog-
ers [43] report that one SD is about 200  ml, and Hrolfs-
dottir [54] reports one SD is about 370 ml, so although an 
exact amount of milk per SD cannot be determined, an esti-
mate between 200 and 350ml seems appropriate.
Two studies (Martin [27] and Ben-Shlomo [28]) stud-
ied the effects of milk intake in childhood and IGF-I and 
IGFBP3 levels in adulthood, and were considered sepa-
rately. The Martin study also included IGF-II and IGFBP2, 
and the results of these were also considered separately.
The association between milk and IGF-I
Of the 31 data points (from 28 studies) included in the main 
IGF-I analysis, 29 data points showed positive associations 
of milk and dairy intake with IGF-I levels compared to two 
data points that showed negative or null associations. The 
estimated standardized effect size was 0.10 SD increase in 
IGF-I per 1 SD increase in milk (estimated range 0.05–0.25 
SDs), from observation of the albatross plot (Fig. 3a). The 
combined p value for a positive association was 2.2 × 10−27. 
All studies with non-Caucasian subjects displayed a posi-
tive association between milk intake and PCa risk; in par-
ticular, two studies [30, 52] had p values of 0.0001 and 
0.001, respectively, and both studies had a sample size of 
less than 100. When considering only Caucasians, the over-
all impression from the albatross plot did not change; the 
effect estimate was still considered to be around 0.10 SD.
Of the 31 data points, 18 had an estimated standard-
ized effect size between 0.05 and 0.25 SDs and four had 
an effect size of more than 0.25 SD. Eleven of these data 
points (61%) used milk as an exposure, including two that 
had an estimated standardized effect size of more than 0.25 
SD [30, 53].
When considering studies that examined the association 
between milk and IGF-I, the 31 data points (from 28 stud-
ies) showed consistency in their direction of effect, as all 
but two associations seen were positive.
The largest effect was seen in the Rich-Edwards study 
[30], where 26 Mongolian children, who had a very low 
Fig. 2  Infographic to illustrate overall associations between milk 
intake and PCa risk (including advanced risk for IGF-I and IGFBP-
3). Notes: numbers next to the circles indicate the total number of 
participants across all studies, the size of each circle is proportionate 
to the p value (larger circles indicate lower p values), the “+” and 
“−” symbols indicate the direction of effect, the two semi‑transparent 
circles in IGF-I and IGFBP-3 PCa Risk indicate advanced PCa risk 
(with associated p values the lower of the two p values), and p val-
ues are all calculated using Stouffer’s Z score method of combining p 
values. *Milk is used as a collective term for milk, dairy products and 
dairy proteins
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baseline milk intake, were given milk supplements; IGF-I 
and IGFBP-3 levels were compared before and after the 
supplementation. At the end of the month, mean IGF-I lev-
els rose from 290.93 ng/ml (SD 93.98 ng/ml) to 358.34 ng/
ml (SD 125.62 ng/ml), an increase of 23% (p < 0.0001). As 
no study deprived the participants of milk/dairy, this study 
is the best estimate of the difference in IGF-I levels between 
very little and some milk intake, although the small number 
of children limit our ability to draw firm conclusions.
A large effect was also seen in the Hoppe study [53], 
where 24 8-year-old children were placed in two equally 
sized groups; the first group was asked to drink 1.5  l of 
skimmed milk per day, the second to eat 250 g of low-fat 
meat per day, with the remaining diet up to choice. Over 7 
days, the IGF-I level of the milk-group children rose from 
209.3 ng/ml (SD 54.9 ng/ml) to 249.0 ng/ml (SD 66.8 ng/
ml), an increase of 19% (p < 0.001), while the IGF-I level 
of the meat-group children did not change. Although both 
these studies were conducted in small numbers of chil-
dren, they both show that large increases in milk intake can 
increase IGF-I levels over a short period of time.
The Cadogan and Zhu RCTs [50, 52] both supple-
mented the diet of children with milk, with a longer fol-
low-up of between 18 and 24 months, and both showed 
that milk increases IGF-I over longer periods, albeit with 
a smaller effect size. The Heaney RCT [51] showed that 
a 12-week milk supplement in older people (mean 65 
years) also increased IGF-I levels. Prospective cohort 
and retrospective studies in general showed a null or 
positive effect, consistent with but generally weaker than 
the RCTs and non-randomized experimental studies. For 
cross-sectional studies, there appeared to be little differ-
ence between studies of children and adults.
The two negative associations seen in the Ben-Shlomo 
and Martin studies were relatively strong, with p val-
ues of 0.01 and 0.06, respectively, and estimated effect 
sizes of between 0.05 and 0.10 SDs [27, 28]. These stud-
ies were not included in the main analysis of IGF-I, as 
the studies had a qualitatively different follow-up period, 
where the exposure (in childhood) was far removed in 
time from the outcome (in adulthood). This is a differ-
ent research question, possibly looking at programming 
of the IGF-I axis rather than a direct effect of milk intake 
on IGF levels [196].
In the Ben-Shlomo study, pregnant mothers were ran-
domized during 1972–1974 to either receive vouchers for 
free milk until the child reached 5 years of age, or to receive 
no vouchers, with the serum IGF levels measured in off-
spring at a mean age of 50 years. In the Martin paper, diets 
and physical health surveys were given to children aged 
between 0 and 19 years (mean age 7 years) in 1937–1939, 
and these children were traced and invited to follow-up in 
2002–2003, when IGF levels were measured.
The association between milk and IGFBP-3
In total, 15 studies presented data for IGFBP-3, one of 
which reported data for two ethnic subgroups. All stud-
ies showed a positive association between milk intake and 
IGFBP-3 levels. The estimated standardized effect size 
was 0.05SD increase in IGFBP3 per 1 SD increase in milk 
(estimated range 0.00 to 0.10 SD, Fig. 3b). The combined 
p value was 4.3 × 10−15. Similar to IGF-I, the three stud-
ies that had the largest effect estimates and smallest P val-
ues used milk as an exposure rather than dairy products or 
protein [36, 45, 53]. There were few non-Caucasian studies 
looking at IGFBP-3, therefore the estimate for Caucasians 
only did not change.
Among studies that had examined the effect of milk on 
IGFBP-3, the 16 data points (from 16 studies) all had a 
positive effect size, centered on an effect size of about 0.05 
SD. Almost all milk-IGFBP-3 studies were prospective 
cohorts or cross-sectional studies with reasonably similar 
effect sizes, regardless of age or ethnicity. Hoppe studied 
both IGF-I and IGFBP-3, and found a positive association 
(smaller than for IGF-I) with a 5% increase in IGFBP-3 in 
the milk-group children (p < 0.05) [53].
Ben-Shlomo and Martin studied IGFBP-3 as well 
as IGF-I [27, 28]; as with IGF-I, these studies were not 
included in the albatross plot due to differences in study 
design. Both studies found very slightly negative asso-
ciations (p = 0.55, p = 0.5, respectively), in contrast to the 
other studies that all found positive associations.
Table 4  Results for all milk–IGF associations, including subgroup 
analyses
Ns number of studies within each analysis, Np number of participants 
across all studies
Outcome Ns Np Effect estimate and 
range (from Albatross 
plots)
All
IGF-I 28 27,408 0.10 (0.05–0.25)
IGF-II 2 12,148 <0.05 (0.00–0.05)
IGFBP-1 2 1,944 0.00 (NA)
IGFBP-2 2 2,940 (− 0.10 to − 0.05)
IGFBP-3 15 24,744 0.05 (0.00–0.10)
Caucasian only
IGF-I 26 15,852 0.10 (0.05–0.25)
IGFBP-3 14 13,935 0.05 (0.00–0.10)
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Fig. 3  Albatross plots for each outcome: a IGF-I and b IGFBP-3, 
stratified by exposure. Each point represents a single study included 
in the meta-analysis, with the effect estimate (represented as a p 
value), plotted against the number of subjects included within each 
study. Effect estimates are standardized beta coefficients. Where p 
values were presented as <0.05, they were plotted as 0.05 as a con-
servative estimate
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The association between milk and other IGF proteins
Two studies examined the association between milk/
dairy protein intake and IGF-II levels; a large study of 
milk intake in elderly Japanese men (p = 0.001) [47] and 
a smaller study of dairy protein intake in Caucasian men 
(p = 0.28) [48]. The studies showed a very weak positive 
association between milk and dairy protein intake and IGF-
II levels (effect estimate: <0.05 SDs, range 0.00–0.05 SDs, 
Supplementary Fig. 1A); the combined p value was 0.001.
There was no suggestion of an association between milk, 
dairy product or dairy protein intake and serum levels of 
IGFBP-1 (effect estimate: 0.00 SD, no range, Supplemen-
tary Fig. 1B), as the two included studies had p values of 
0.39 and 0.83, respectively, and effect estimates in opposite 
directions [46, 49]. The combined P value was 0.32.
The two studies which examined the association between 
milk/dairy protein and IGFBP-2 levels both suggested that 
intake of dairy products and dairy protein led to a small 
decrease in serum levels of IGFBP-2 (effect estimate 
between −0.10 and −0.05 SDs Supplementary Fig.  1C); 
the combined p value was 0.00021.
The Martin study [27] also examined IGF-II and IGFBP-
2, which both showed a slight negative association with p 
values of 0.5 and 0.3, respectively.
IGF–Prostate Cancer: human studies
Circulatory levels of IGF and Prostate Cancer risk
In total, 59 studies were included in this meta-analysis, 
consisting of 18 prospective and 41 retrospective studies. 
Nine studies had not been included in the Rowlands 2012 
paper [129, 133, 134, 142, 147, 148, 152–154] and eight 
studies that were included in the Rowlands 2012 analysis 
were excluded due to critical RoB [175–178, 180–183]. 
Data were extracted for all five IGF and IGFBP peptides. 
All results presented are from random effects meta-analy-
sis, with fixed effect results commented on if necessary.
OR values (95% CI) per SD of exposure increase for 
retrospective and prospective values combined were as 
follows (Table  5): IGF-I, n studies = 51, OR 1.09 (95% 
CI 1.03, 1.16) (Fig.  4); IGF-II, n = 10, OR 1.07 (0.97, 
1.18); IGFBP-1, n = 4, OR 1.02 (0.77, 1.34); IGFBP-2, 
n = 6, OR 1.07 (0.91, 1.25); and IGFBP-3, n = 39, OR 
0.90 (0.83, 0.98) (Fig. 5). Overall, there was a moderate-
to-high degree of inconsistency across the studies for all 
five IGF and IGFBP peptides  (I2 66–88%; Supplemen-
tary Fig. 2) and the inconsistency within the retrospective 
data was consistently greater compared to prospective 
studies. Due to extreme outliers, the fixed effects meta-
analysis result for IGFBP-3 shows a very small positive 
association with PCa risk, whereas the random effects 
result shows a small negative association (fixed OR 1.02 
[1.00, 1.04]; random OR 0.90 [0.83, 0.98]).
Correspondingly, there was some evidence of small 
study effects in IGFBP-3 studies, possibly indicating 
publication bias; Egger’s test p = 0.02, with funnel plots 
showing that retrospective studies were responsible for a 
greater degree of heterogeneity and more extreme effects 
(Supplementary Fig.  3). IGF-I studies also showed ret-
rospective studies to be more inconsistent, but Egger’s 
test showed no evidence of small study effects, p = 0.44. 
No other exposures showed signs of publication bias or 
small study effects in either funnel plots or Egger’s tests. 
There was no association between sample size and OR 
when performing meta-regression on prospective IGF-I 
(p = 0.68) or IGFBP-3 (p = 0.99) studies.
Subgroup analyses
Advanced prostate cancer risk Data for advanced PCa 
risk and IGF-I and IGFBP-3 were presented in 12 studies 
each. OR values (95% CI) per standard deviation of expo-
sure increase for retrospective and prospective studies com-
bined were as follows: IGF-I, n = 12, OR 1.04 (0.94, 1.14) 
and IGFBP-3, n = 12, OR 0.95 (0.87, 1.03) (Supplementary 
Fig.  4). Egger’s test and funnel plots showed small study 
effects and publication bias for IGFBP-3 (p = 0.006), but not 
IGF-I (p = 0.55). The estimates for advanced PCa risk and 
all PCa risk were not materially different for either IGF-I or 
IGFBP-3 (p = 0.41 and p = 0.37, respectively).
Retrospective versus  prospective studies Inconsistency 
was much greater among retrospective studies compared 
to prospective studies across all subgroup analyses and 
overall. OR values were consistently higher in all retro-
spective analyses for all five IGF or IGFBP peptides, with 
the exception of IGFBP-3, which was slightly lower (for 
IGFBP-3: retrospective OR 0.84 [0.71, 0.99]; prospective 
OR 1.02 (0.99, 1.05); p = 0.01 for difference between pro-
spective and retrospective studies) (see Table 5).
PSA screened versus  clinically detected In total, there 
were far fewer studies that used PSA screening to detect 
cases (n = 6) compared to those where cases were identi-
fied clinically (n = 59). Overall, there was no discernible 
trend in the effect of PCa detection methods on IGF lev-
els and PCa risk (Table 5). The only distinct difference in 
OR values between these two subgroups was in IGFBP-3, 
where the PSA-detected PCa OR was 1.06 (0.94, 1.19), 
higher than the clinically detected PCa OR of 0.87 (0.79, 
0.97), p = 0.02.
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Genetic data
In total, 18 studies presented data relevant to genes or 
SNPs within the IGF pathway, in relation to PCa risk. 
Of these, data for only two polymorphisms: IGF-I (CA)
n repeat and IGFBP-3 SNP-202A/C, were presented 
in three or more studies, allowing for meta-analyses. 
Another 46 SNPs or genes were identified in the review; 
however, only one set of data was available for 42 
of the SNPs and two sets of data for four of the SNPs 
Fig. 4  Forest plot for all studies that presented data on circulatory levels of IGF-I in relation to PCa risk, stratified by study design (prospective 
vs retrospective) and PSA-detected PCa cases
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(Supplementary Table 2). Again, all results presented are 
from random effects meta-analysis.
OR values (95% CI) for the two meta-analysable poly-
morphisms, were as follows: IGF-I (CA)n (n = 5 studies) 
when compared against a 19/19 repeat, where X is anything 
other than 19, the X/X repeat had an OR 0.98 (0.56, 1.73), 
and X/19 repeat had an OR 0.99 (0.63, 1.55). For IGFBP-
3-202A/C SNP (n = 8 studies), when compared against the 
A/A allele, the A/C allele had an OR 1.22 (0.84, 1.79), and 
the C/C allele had an OR 1.51 (1.03, 2.21) (Supplementary 
Fig. 5).
IGF–prostate cancer: animal models
Of the 10 animal studies included in the analysis (Table 6), 
eight provided data on mechanistic IGF pathways, in rela-
tion to PCa risk or progression. Four of these studies were 
transgenic mice models, which over-expressed [186] or 
Fig. 5  Forest plot for all studies that presented data on circulatory levels of IGFBP-3 in relation to PCa risk, stratified by study design (prospec-
tive vs retrospective) and PSA-detected PCa cases
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knocked-out IGFBP‑3 [189], or knocked-out IGF‑IR [187] 
or IGF‑I [188]. The remaining four studies were xenograft 
models that used antibodies to bind to IGF peptides [190, 
193] or IGF-IR [191] or IGFBP-3 [192].
Seven out of the eight studies found statistically signifi-
cant differences between experimental and control models, 
with a small level of consistency between results (Table 6). 
Two studies found a positive association between tumor 
progression and IGFBP-3 suppression or deficiency [189, 
192], while another found tumor size to be smaller within 
mice that over-expressed IGFBP-3 [186]. In addition, both 
studies that provided data on IGF-II found that IGF-II sup-
pressed mice had significantly smaller tumors [190, 193]. 
Two studies had contradictory results with regards to IGF 
receptors (IGF-IR), in that deleted IGF-IR accelerated the 
emergence of aggressive PCa in one experimental model 
[187], while in another tumors were smaller in IGF-IR sup-
pressed mice [191].
One animal study investigated the association between 
loss of imprinting in IGF-II and PCa susceptibility [195]. 
The paper was a short communication and did not provide 
enough data to be included in the main analysis; however, it 
was included as supporting evidence. The remaining stud-
ies presented only data on the hallmarks of cancer as out-
comes and were therefore also included only in supporting 
evidence [194].
Supporting evidence
In total, 49 studies were included within the supporting 
evidence category; 16 of these studies investigated the 
association between circulating levels of IGF-I (n = 14), 
IGF-II (n = 2), IGFBP-2 (n = 2) or IGFBP-3 (n = 8) with 
prostate cancer risk or prostate cancer outcomes such as 
Gleason grade, TNM stage or PSA-progression free sur-
vival. 18 studies investigated the association between tissue 
expression of IGF-I (n = 5), IGF-II (n = 4), IGF-IR (n = 7), 
IGFBP-2 (n = 7), IGFBP-3 (n = 6) with risk of prostate can-
cer or prostate cancer outcomes such as Gleason Grade or 
TNM stage. Fifteen studies investigated whether genetic or 
epigenetic variations in the IGF‑I (n = 5), IGF‑II (n = 7), 
IGFBP‑2 (n = 2) or IGFBP‑3 (n = 3) gene were associ-
ated with prostate cancer risk or outcomes such as Glea-
son score, TNM stage, PSA recurrence or survival. Results 
from individual studies were generally not consistent with 
each other, and therefore did not influence our overall 
conclusions. The results are presented in Supplementary 
Tables 3, 4 and 5.
Risk of bias and GRADE
Generally there was a moderate RoB across the majority of 
study types, with the exception of animal models where the 
overall RoB was ‘unclear’ due to the lack of information pro-
vided within the papers to inform a number of the RoB sub-
categories. Only 11 human observational studies were classed 
as having critical RoB, and therefore excluded from the meta-
analysis on this basis. All but one of the human RCTs in the 
Milk–IGF analysis were given an ‘unclear’ RoB rating, due 
to the lack of data to inform particular RoB sub-categories.
The overall GRADE assessments found that there was 
moderate evidence from human studies that milk intake 
increased IGF-I levels and there is low-level evidence 
that milk reduces IGFBP-3 levels. We also found moder-
ate evidence from human studies that increasing IGF-I lev-
els increases prostate cancer and advanced prostate cancer 
risk, and low-level evidence of no effect of IGFBP-3 lev-
els on prostate cancer and advanced prostate cancer risk. It 
should be noted that although the evidence for an association 
between IGF-I and prostate cancer was strong, observational 
studies cannot by themselves offer strong evidence for causal 
associations; therefore there is only moderate evidence that 
IGF-I levels increases prostate cancer risk. For associations 
between all other IGF biomarkers, there was very low-level 
evidence of any effect. Common reasons for downgrading 
were imprecision (especially for IGF biomarkers which had a 
small number of studies) and publication bias. For full details 
on GRADE assessments, see Supplementary Tables 6, 7, 8, 
9, 10, 11, 12, 13, 14, 15, 16, 17, and 18.
The animal studies were collectively found to offer 
very low-level evidence that the IGF pathway was related 
to prostate cancer risk. The reasons for this are as follows: 
(1) although they were all experimental studies, they had 
unclear risk of bias due to a lack of information on key 
variables; (2) we were unable to look at consistency across 
studies as each study was very different from the other; (3) 
we downgraded animal studies for indirectness because 
in the animal studies, components of the IGF pathway 
were over-expressed to very high levels or knocked out 
which does not reflect variation within the normal range 
in humans. In addition, animal studies measured outcomes 
in terms of tumor weight or volume rather than incidence; 
the level of imprecision was generally high due to the small 
number of animals in each experiment and the inability to 
combine across very different studies. Finally we felt that 
there was likely to be substantial publication bias. It should 
be noted, however, that GRADE assessments were designed 
for use in human studies rather than animal studies.
Discussion
Milk–IGF
Based on the overall synthesis of data, there was moder-
ate evidence to suggest that milk intake was positively 
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associated with increased levels of IGF-I and IGFBP-3. 
This trend appeared to be greater in studies that consisted 
of non-Caucasian subjects, particularly in IGF-I, and sup-
ports results from previous studies that demonstrate that 
ethnicity can be a contributing factor to increased levels of 
circulating IGF. It is not possible in this review to elucidate 
whether ethnicity or differences in normal milk intake have 
caused these differences. However, although there may 
be a true difference between ethnicities, it is more likely 
that lower milk intake in non-Caucasian ethnicities causes 
larger effects of milk on IGFs, both in experiments where 
milk is added to the diet and in observational studies where 
the range of milk intake is much larger.
Across both analyses for IGF-I and IGFBP-3, the largest 
effect on IGF levels was seen when milk was used as an 
exposure, rather than dairy protein or its products. Studies 
in the IGFBP-3 analysis, that used dairy protein or products 
as exposures, were not seen to contribute to the overall pos-
itive association; rather this association was observed only 
in those studies that used milk as a standalone exposure. 
Although the original search terms for this analysis were 
designed to include dairy protein and products as addi-
tional exposures, to ensure a broad coverage of exposure 
types that could include milk, the overall results suggest 
that ‘diluted’ exposure categories may not be as pertinent 
in elucidating the true association between milk and IGF 
levels.
The analysis of IGFBP-2 in this arm of the study con-
sisted of only two studies, both of which classified the 
exposures as dairy protein and products. Despite the small 
number of studies and ‘diluted’ exposure types, the analy-
sis produced weak evidence to suggest that IGFBP-2 levels 
decrease with these types of exposures. Speculatively, fur-
ther studies using milk alone as an exposure may be useful 
to ascertain whether there is a stronger negative association 
between IGFBP-2 and milk intake, compared to the results 
in this analysis that may be under-powered. Additionally, a 
similar observation can be made for the weak positive asso-
ciation that was found between IGF-II and milk and dairy 
protein, as only two studies provided data for this protein.
IGFBP-1 was the only protein to produce a null associa-
tion with milk and dairy proteins and products; however, 
there were only two studies available for this analysis, both 
of which used dairy product or protein as an exposure. 
Overall, the analyses of the small number of studies availa-
ble for IGF-II, IGFBP-1, and IGFBP-2 present a more con-
servative estimate of the effect of milk on levels of these 
proteins and warrant further data to confirm the presence or 
absence of any associations.
Overall there was a large amount of data for the 
milk–IGF analysis, however, there was considerable 
inconsistency within study design that made it difficult to 
assimilate the results in such a way to produce a statistic 
that would represent the associations present across all the 
studies as a whole. As part of the analysis, we were able 
to account for ethnicity by differentiating these sets of 
data within the albatross plots, but other aspects of study 
design were more difficult to account for. One of the main 
divisions between study types were those that followed up 
interventions over weeks or months and those that followed 
interventions up after a number of years; essentially provid-
ing data for short-term and long-term consequences of milk 
interventions. Studies with a different study design, which 
looked at milk exposure in childhood and IGF levels in 
adulthood, were considered separately as these may reflect 
a programming effect, rather than a direct effect.
One possibility for the apparent shift from a positive 
association between milk and IGF-I in the short term to a 
negative association in the long term is programming of the 
IGF axis in childhood [196]. The theory developed in this 
study is that high milk consumption in childhood increases 
IGF-I in the short term; this leads to feedback and pro-
gramming of the IGF axis, which modulates the amount of 
IGF-I in the body, leading to a reduced amount of IGF-I in 
adulthood.
IGF–Prostate cancer
The results from our IGF–PCa analysis reflect those from 
the previous meta-analysis [8]; however, the strength of the 
associations seen in the current paper appears to be smaller; 
OR values for all IGF proteins in this study were between 
0.90 (IGFBP-3) and 1.09 (IGF-I), compared to between 
0.88 (IGFBP-3) and 1.21 (IGF-I) in the earlier Rowlands 
study [7]. However, the directions of effect for all IGF pro-
teins were consistent between this study and Rowlands, and 
all results had p values above 0.05 when testing for differ-
ences between estimates [20], there is therefore no evidence 
to suggest that the results were inconsistent. The standard 
errors of the current study’s estimates were all lower than 
in the Rowlands study, indicating greater precision.
These differences in estimates and precision may in 
part be due to more rigorous risk of bias protocols, which 
have ensured that the quality of the data presented here is 
high and that confounding factors (with particular focus on 
age) have been accounted for. Eight papers, consisting of 
941 PCa cases, were included in the Rowlands analysis and 
were excluded in this study due to age not being considered 
in the design or analysis of the studies. This may account 
for some of the differences between the results between the 
current versus the earlier Rowlands study [8]. The addi-
tion of studies published after 2012 may have also affected 
the results. Additionally, an evaluation of meta-analyses of 
biomarker associations with cancer risk [197] concluded 
that there may be bias present specifically in the meta-
analyses of IGF with cancer risk, of which the Rowlands 
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meta-analysis was one; by removing studies with the high-
est risk of bias, it is possible some bias has been removed. 
This study thus provides a refined and updated assessment 
of the previous IGF–PCa association.
Both the current study and the Rowlands study, showed 
a marked difference between the quality of retrospective 
and prospective studies, both in terms of heterogeneity and 
possible publication bias; retrospective studies in general 
had a larger amount of inconsistency and displayed more 
non-symmetry in funnel plots. All eight studies excluded 
from this study, but included in Rowlands, were retrospec-
tive; this may have contributed to the relative imprecision 
of the Rowlands results, as well as making those results 
more extreme.
In our current study, there were few differences between 
the results from studies with clinically detected vs PSA-
detected PCa (Table  5); while there may simply be few 
differences between IGF and PSA or clinically detected 
PCa, it is more likely that the lack of difference is due to 
the difficulty in ascertaining the method by which the PCa 
cases are found and recruited, and may reflect the ubiq-
uity of the screening for PCa using the PSA in the general 
population. As PSA testing has become the normal method 
of testing for prostate cancer in the USA and many other 
countries worldwide, prostate cancer cases are being found 
earlier and with more indolent disease. Thus, newer stud-
ies likely have a different case-mix to earlier studies, with 
a greater proportion of early and indolent cancers. If IGF 
action on prostate cancer affects progression as well as (or 
as opposed to) incidence, then the overall effect estimate 
of IGF on prostate cancer will be reduced by a change 
in case-mix favoring indolent cancers. It is possible that 
some of the differences between this study and the Row-
lands study were as a result of changing the case-mix by 
excluding older studies, which may have had more clinical 
cases, (with critical risk of bias) and including newer stud-
ies, which may have had more PSA-detected cases. How-
ever, this is balanced by our finding showing that advanced 
prostate cancer risk was no more associated with IGF-I 
and IGFBP-3 than prostate cancer risk as a whole; if IGF 
was associated with progression, it would likely be seen 
when examining advanced prostate cancer risk. However, 
advanced prostate cancer was defined differently between 
studies and may not be representative of cancers that have 
“progressed,” especially as the advanced cancers may have 
been found earlier through PSA testing.
Within the genetic portion of the IGF–PCa analysis, 
the C/C genotype of the IGFBP-3 SNP-202A/C, pre-
sented a strong, positive association with PCa risk (OR 
1.51), alongside a moderate association with the A/C 
genotype of the same SNP (OR 1.22). This genotype 
is associated with a higher IGF-I level relative to the 
A/A genotype [198], and therefore the finding supports 
the hypothesis that IGF-I is positively associated with 
PCa risk. Repeats of (CA) did not provide evidence for 
any association between IGF-I and PCa risk, but only 
5 studies were included, which had very inconsistent 
results; Schildkraut [170] estimated an odds ratio of 3.33 
(1.26–8.82) for 19/19 repeats against non-19/non-19 
repeats, whereas Tsuchiya [165] estimated an odds ratio 
of 0.30 (0.12–0.77). This may be due to differences in 
study populations: Schildkraut recruited men in the USA, 
with a prevalence of 27% for the 19/19 allele; Tsuchiya 
recruited men in Japan, with a prevalence of only 6% for 
the 19/19 allele.
Although a larger number of studies provided data that 
was eligible for the genetic analysis, only two alleles had 
enough data to be meta-analyzed. Overall, there is a dis-
tinct lack of data with regards to many other genes and 
SNPs within the IGF pathway, with the majority of SNPs 
only being studied within one population within one study.
A recent Mendelian randomization study of the IGF 
pathway and prostate cancer [199] concluded that the 
IGF pathway may be associated with prostate cancer, but 
because of the potential for pleiotropy, no individual IGF 
protein could be identified as having a specific association.
When we subjected the evidence to GRADE assess-
ments, we found that at best there was moderate evidence 
of an association for milk–IGF-I and milk–IGFBP-3, but 
for the most part, the evidence was of a low or very low 
level. GRADE takes into account the totality of evidence to 
determine the overall strength of a reported association and 
the potential for it to have been influenced by bias. As most 
of the evidence on both milk and the IGF pathway, and the 
IGF pathway and prostate cancer was observational, there is 
a great deal of potential for bias to have occurred. In addi-
tion for some biomarkers (IGF-II, IGFBP-1 and IGFBP-2), 
the small number of studies carried out meant that the level 
of imprecision was high. These results indicate that even 
for the IGF-I–prostate cancer association where many stud-
ies have previously been focused, the evidence that IGF-I 
increases prostate cancer risk is not strong, and there is a 
need for further high-quality studies that are free from bias 
to address this question. To our knowledge, GRADE has 
not previously been applied to animal studies in this way, 
the main reasons why these studies scored so low in this 
assessment was the lack of information on experimental 
methods, the lack of similar studies to assess consistency 
and the potential for publication bias. As noted, however, 
GRADE was developed for use in human studies and may 
not be appropriate when considering animal studies, which 
have very different methodologies. Additionally, while ani-
mal studies may not be suitable for assessing the strength 
of the evidence underlying mechanistic pathways, they may 
be extremely useful in identifying and highlighting mecha-
nisms which can then be tested in human studies.
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Combining results from the milk–IGF and IGF–
prostate cancer analysis
When looking at the overall results from the milk–IGF and 
IGF–PCa data, IGF-I and IGFBP-3 are possible mediators 
of the association between milk intake and PCa. Broadly 
speaking, the data from this study lend support to the 
hypothesis that increased milk intake may increase circulat-
ing levels of IGF-I, which in turn may increase the risk of 
PCa.
There is also evidence to suggest that levels of circulat-
ing IGBP-3 can be increased by milk intake; however, this 
binding protein appears to have a protective effect against 
PCa risk (Fig. 5). This finding was only seen in retrospec-
tive studies; as such, it should be interpreted with appro-
priate caution as prospective studies are generally more 
robust.
These associations are mediated by key factors within 
both arms of the study, most importantly, length of follow-
up across both arms, baseline intake of milk and dairy and 
ethnicity within the milk–IGF studies and age within the 
IGF–PCa studies. Within this meta-analysis, the methodol-
ogy was designed to account for these factors to ensure that 
they did not bias the overall result. However, combining the 
effects from differing populations may mask stronger or 
weaker associations among these populations as individual 
entities, and therefore the results should be carefully inter-
preted in this respect.
Results for IGF-II, IGFBP-1, and IGFBP-2 across both 
arms of the study do not suggest a complete pathway to link 
milk intake to PCa risk via these IGFs; this is due largely to 
the paucity of studies examining these biomarkers, future 
studies may contribute to our understanding.
It should be noted that although the results sup-
port short-term milk intake being associated with IGF-I 
increase, long-term associations may be complicated by 
programming of the IGF axis. Therefore, drinking milk in 
childhood may not be associated with prostate cancer risk 
in the future, whereas drinking milk in adulthood may be; 
this may have a biological basis, as milk is a food evolved 
for neonates rather than adults.
Supporting evidence and animal studies
Animal models can provide evidence to support mechanis-
tic pathways that connect IGF as an intermediate phenotype 
between milk intake and PCa risk; however, the application 
of these within a human-based review requires caution. The 
data from animal studies and results from supporting evi-
dence studies were highly heterogeneous, encompassing 
a large variety of study designs, outcomes and exposures 
relating to IGF and PCa risk; as such, it was not possible 
to carry out detailed meta-analyses for these data. When 
IGF-I levels were reduced by producing antibodies against 
IGF-I [190], tumor volume was reduced relative to controls, 
whereas tumor volume was higher in IGFBP-3 knockout 
animals [189]. These studies therefore support the associa-
tions that were found within the human IGF–PCa analysis.
When assimilating the data from all the supporting evi-
dence studies, the results were conflicting. The studies had 
looked at the effect of cancer treatment on IGF levels, how 
IGF levels changed over time in prostate cancer patients, 
the association between IGF levels and precancerous 
lesions, the expression of IGF in prostate cancer tissue vs 
normal prostate and other tissue, haplotypes in IGF-I and 
prostate cancer risk, SNPs in the IGF pathway and cancer 
survival, loss of IGF‑II imprinting and cancer risk, and 
methylation of IGF genes. These data provided evidences 
for positive, negative, and null associations between IGF 
exposures and PCa risk, with positive associations as the 
most prevalent associations.
Limitations
An important limitation of this work is that the studies 
examining the association between milk and IGF did not 
include sufficient data to perform a meta-analysis, and thus 
a combined effect estimate could not be calculated. How-
ever, the albatross plots allowed an approximate exami-
nation of the underlying magnitude of effect in terms of 
standardised mean differences, allowing conclusions to 
be drawn about the likely size of the association between 
milk and different IGFs. We acknowledge that the litera-
ture search was completed in March 2014, and therefore 
more recent relevant studies may have been missed. How-
ever, one particular strength of this study is the inclusion of 
many different data types, and the application of the Risk 
of Bias and GRADE tools to the data allowing for a more 
robust conclusion.
Conclusion
The diversity of studies created a complex meta-analysis 
structure, which has required strict inclusion/exclusion 
criteria to allow meta-analysable data across a number of 
study types. Overall, the combined evidence from human 
and animal observational, experimental, and genetic studies 
provides evidence to support a role of the IGF pathway, in 
particular IGF-I in explaining the association between milk 
and prostate cancer.
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